Mon, Jun 24, 4:15 PM (75 days ago)
Regenerex Pharma, Inc., a Nevada-based company, specializes in developing and marketing wound care products. For the fiscal year ended March 31, 2024, the company reported no revenue and a net loss of $3,543,827, up from $137,330 the previous year, primarily due to increased payroll and R&D expenses. Operating expenses totaled $3,465,825. The company raised $393,250 through common stock and warrants sales and notes payable of $123,844. Key products include Xcellderma OTC, Accelerex Sterile Wound Cream, and Accelerex Impregnated Sterile Wound Dressing, targeting chronic and acute wounds. The company aims to capture significant market share in the U.S. and globally. Strategic initiatives include developing managed care agreements and negotiating with Middle Eastern distributors. Liquidity concerns persist, with significant cash needed to launch operations. The company has substantial current liabilities and negative working capital, raising doubts about its ability to continue as a going concern. Management is actively seeking additional financing.